Drug Profile
OMS 527
Alternative Names: OMS-182399; OMS527; PDE7 inhibitor - Omeros; Type 7 cyclic nucleotide phosphodiesterase inhibitor - OmerosLatest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator Asubio Pharma
- Developer National Institute of Drug Abuse; Omeros Corporation; The Parkinsons Institute and Clinical Center
- Class Antiparkinsonians; Drug withdrawal therapies; Small molecules
- Mechanism of Action Type 7 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Impulse control disorders; Movement disorders; Substance-related disorders
- Phase Unknown Dyskinesias